|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Mhc class i complex
|
 |
|
Title:
|
 |
Hfe (human) hemochromatosis protein
|
|
Structure:
|
 |
Hfe. Chain: a, c. Engineered: yes. Beta-2-microglobulin. Chain: b, d
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Organ: ovary. Gene: hfe. Expressed in: cricetulus griseus. Expression_system_taxid: 10029. Expression_system_cell_line: cho. Organ: ovary
|
|
Biol. unit:
|
 |
Dimer (from
)
|
|
Resolution:
|
 |
|
2.60Å
|
R-factor:
|
0.233
|
R-free:
|
0.277
|
|
|
Authors:
|
 |
J.A.Lebron,M.J.Bennett,D.E.Vaughn,A.J.Chirino,P.M.Snow, G.A.Mintier,J.N.Feder,P.J.Bjorkman
|
Key ref:
|
 |
J.A.Lebrón
et al.
(1998).
Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor.
Cell,
93,
111-123.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
04-Mar-98
|
Release date:
|
23-Mar-99
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
|
|
|
 |
|
 |
|
 |
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
|
 |
|
Cellular component
|
extracellular region
|
8 terms
|
 |
|
Biological process
|
immune response
|
8 terms
|
 |
|
Biochemical function
|
protein binding
|
1 term
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Cell
93:111-123
(1998)
|
|
PubMed id:
|
|
|
|
|
| |
|
Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor.
|
|
J.A.Lebrón,
M.J.Bennett,
D.E.Vaughn,
A.J.Chirino,
P.M.Snow,
G.A.Mintier,
J.N.Feder,
P.J.Bjorkman.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
HFE is an MHC-related protein that is mutated in the iron-overload disease
hereditary hemochromatosis. HFE binds to transferrin receptor (TfR) and reduces
its affinity for iron-loaded transferrin, implicating HFE in iron metabolism.
The 2.6 A crystal structure of HFE reveals the locations of hemochromatosis
mutations and a patch of histidines that could be involved in pH-dependent
interactions. We also demonstrate that soluble TfR and HFE bind tightly at the
basic pH of the cell surface, but not at the acidic pH of intracellular
vesicles. TfR:HFE stoichiometry (2:1) differs from TfR:transferrin stoichiometry
(2:2), implying a different mode of binding for HFE and transferrin to TfR,
consistent with our demonstration that HFE, transferrin, and TfR form a ternary
complex.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 1.
Figure 1. Crystal Structure of HFE and Comparison to a
Class I MHC Molecule(A) Ribbon diagram shows that HFE resembles
class I molecules in the fold of the heavy chain (blue) and in
its association with the β2m light chain (green). Cys-260, the
residue substituted in the Cys260Tyr mutation, disulfide bonds
with Cys-203.(B) Ribbon drawing of a top view of the HFE α1-α2
platform. His-41 (red), the site of the His41Asp mutation,
interacts with Asp-73 (green).(C) The HFE model in the region of
the Cys-260—Cys-203 disulfide bond is shown superimposed on a
2F[o]−F[c] annealed omit electron density map ([21]) contoured
at 1σ. The average B factor for the residues shown is 48
Å^2.(D) Close-up of a histidine cluster and nearby
tyrosine located underneath the right-hand side of the platform.
His-94 is found in class I MHC molecules (class I His-93);
His-89 and His-123 are present only in human ([16]), rat (EMBL
accession number AJ001517), and mouse ( [20]) HFE. His-87 is
present in human, but not mouse or rat, HFE.(A), (B), and (D)
were made with Molscript ([28]) and rendered with Raster3D (
[34]). (C) was prepared with O ( [23]).
|
 |
Figure 2.
Figure 2. The Counterpart of the Class I Peptide-Binding
Groove is Narrowed in HFE by Translation of the α1 Helix(A) Cα
stereo superpositions based on Cα atoms in the platform β
strands of HFE with class I and class I–related proteins. Top,
HLA-A2 (green, including a ball-and-stick representation of
bound peptide; PDB code 2CLR) and HFE (magenta). Heavy chains
share 37% amino acid sequence identity. Middle, Rat FcRn (green;
PDB code 1FRU) and HFE (magenta). Heavy chains share 28%
sequence identity. HFE Pro-166 (labeled) is analogous to FcRn
Pro-162, located at a kink in the FcRn α2 helix. Bottom, Mouse
CD1 (green) ([50]) and HFE (magenta). Heavy chains share 22%
sequence identity. HFE Pro-166 (labeled) is analogous to CD1
Pro-162, located at a kink in the CD1 α2 helix.(B)
Peptide-binding groove of HLA-A2 with labeled binding
pockets.(C) HFE counterpart of the class I binding groove
showing residues that would clash with a bound peptide. HFE side
chains shown in white (same in HFE and HLA-A2) and green
(different in HFE and HLA-A2) have at least two steric clashes
with polyalanine versions of four different nonameric peptides
(from HLA-A2 structures, PDB codes 1HHG, 1HHI, 1HHJ, and 1HHK;
[30]) that were superimposed upon HFE after alignment of HLA-A2
and HFE. Steric clashes are defined as occurring when atoms are
closer than the sum of their van der Waals radii minus 0.4
Å. The blue side chain would clash with peptides
containing side chains larger than alanine.All panels were made
with Molscript ([28]) and rendered with Raster3D ( [34]).
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Cell Press:
Cell
(1998,
93,
111-123)
copyright 1998.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
P.Ramos,
E.Guy,
N.Chen,
C.C.Proenca,
S.Gardenghi,
C.Casu,
A.Follenzi,
N.Van Rooijen,
R.W.Grady,
M.de Sousa,
and
S.Rivella
(2011).
Enhanced erythropoiesis in Hfe-KO mice indicates a role for Hfe in the modulation of erythroid iron homeostasis.
|
| |
Blood, 117,
1379-1389.
|
 |
|
|
|
|
 |
D.A.Rhodes,
L.H.Boyle,
J.M.Boname,
P.J.Lehner,
and
J.Trowsdale
(2010).
Ubiquitination of lysine-331 by Kaposi's sarcoma-associated herpesvirus protein K5 targets HFE for lysosomal degradation.
|
| |
Proc Natl Acad Sci U S A, 107,
16240-16245.
|
 |
|
|
|
|
 |
H.Li,
and
Y.Z.Ginzburg
(2010).
Crosstalk between Iron Metabolism and Erythropoiesis.
|
| |
Adv Hematol, 2010,
605435.
|
 |
|
|
|
|
 |
J.Gao,
J.Chen,
I.De Domenico,
D.M.Koeller,
C.O.Harding,
R.E.Fleming,
D.D.Koeberl,
and
C.A.Enns
(2010).
Hepatocyte-targeted HFE and TFR2 control hepcidin expression in mice.
|
| |
Blood, 115,
3374-3381.
|
 |
|
|
|
|
 |
K.Ikuta,
A.Yersin,
A.Ikai,
P.Aisen,
and
Y.Kohgo
(2010).
Characterization of the interaction between diferric transferrin and transferrin receptor 2 by functional assays and atomic force microscopy.
|
| |
J Mol Biol, 397,
375-384.
|
 |
|
|
|
|
 |
L.Bhatt,
C.Murphy,
L.S.O'Driscoll,
M.Carmo-Fonseca,
M.W.McCaffrey,
and
J.V.Fleming
(2010).
N-glycosylation is important for the correct intracellular localization of HFE and its ability to decrease cell surface transferrin binding.
|
| |
FEBS J, 277,
3219-3234.
|
 |
|
|
|
|
 |
L.Li,
C.J.Fang,
J.C.Ryan,
E.C.Niemi,
J.A.Lebrón,
P.J.Björkman,
H.Arase,
F.M.Torti,
S.V.Torti,
M.C.Nakamura,
and
W.E.Seaman
(2010).
Binding and uptake of H-ferritin are mediated by human transferrin receptor-1.
|
| |
Proc Natl Acad Sci U S A, 107,
3505-3510.
|
 |
|
|
|
|
 |
M.Chloupková,
A.S.Zhang,
and
C.A.Enns
(2010).
Stoichiometries of transferrin receptors 1 and 2 in human liver.
|
| |
Blood Cells Mol Dis, 44,
28-33.
|
 |
|
|
|
|
 |
M.M.Speeckaert,
R.Speeckaert,
and
J.R.Delanghe
(2010).
Biological and clinical aspects of soluble transferrin receptor.
|
| |
Crit Rev Clin Lab Sci, 47,
213-228.
|
 |
|
|
|
|
 |
M.Shvartsman,
E.Fibach,
and
Z.I.Cabantchik
(2010).
Transferrin-iron routing to the cytosol and mitochondria as studied by live and real-time fluorescence.
|
| |
Biochem J, 429,
185-193.
|
 |
|
|
|
|
 |
R.Leverence,
A.B.Mason,
and
I.A.Kaltashov
(2010).
Noncanonical interactions between serum transferrin and transferrin receptor evaluated with electrospray ionization mass spectrometry.
|
| |
Proc Natl Acad Sci U S A, 107,
8123-8128.
|
 |
|
|
|
|
 |
S.J.Thorpe,
A.Heath,
G.Sharp,
J.Cook,
R.Ellis,
and
M.Worwood
(2010).
A WHO reference reagent for the Serum Transferrin Receptor (sTfR): international collaborative study to evaluate a recombinant soluble transferrin receptor preparation.
|
| |
Clin Chem Lab Med, 48,
815-820.
|
 |
|
|
|
|
 |
S.V.Mikhailova,
V.N.Babenko,
M.I.Voevoda,
and
A.G.Romashchenko
(2010).
The ethnospecific distribution of the HFE haplotypes for IVS2(+4)t/c, IVS4(-44)t/c, and IVS5(-47)g/a in populations of Russia and possible effects of these single-nucleotide polymorphisms in splicing.
|
| |
Genet Test Mol Biomarkers, 14,
461-469.
|
 |
|
|
|
|
 |
A.I.Mendes,
A.Ferro,
R.Martins,
I.Picanço,
S.Gomes,
R.Cerqueira,
M.Correia,
A.R.Nunes,
J.Esteves,
R.Fleming,
and
P.Faustino
(2009).
Non-classical hereditary hemochromatosis in Portugal: novel mutations identified in iron metabolism-related genes.
|
| |
Ann Hematol, 88,
229-234.
|
 |
|
|
|
|
 |
A.Shander,
M.D.Cappellini,
and
L.T.Goodnough
(2009).
Iron overload and toxicity: the hidden risk of multiple blood transfusions.
|
| |
Vox Sang, 97,
185-197.
|
 |
|
|
|
|
 |
D.J.Yoon,
D.S.Chu,
C.W.Ng,
E.A.Pham,
A.B.Mason,
D.M.Hudson,
V.C.Smith,
R.T.MacGillivray,
and
D.T.Kamei
(2009).
Genetically engineering transferrin to improve its in vitro ability to deliver cytotoxins.
|
| |
J Control Release, 133,
178-184.
|
 |
|
|
|
|
 |
J.Gao,
J.Chen,
M.Kramer,
H.Tsukamoto,
A.S.Zhang,
and
C.A.Enns
(2009).
Interaction of the hereditary hemochromatosis protein HFE with transferrin receptor 2 is required for transferrin-induced hepcidin expression.
|
| |
Cell Metab, 9,
217-227.
|
 |
|
|
|
|
 |
V.Castillo,
and
S.Ventura
(2009).
Amyloidogenic regions and interaction surfaces overlap in globular proteins related to conformational diseases.
|
| |
PLoS Comput Biol, 5,
e1000476.
|
 |
|
|
|
|
 |
Z.Yang,
A.P.West,
and
P.J.Bjorkman
(2009).
Crystal structure of TNFalpha complexed with a poxvirus MHC-related TNF binding protein.
|
| |
Nat Struct Mol Biol, 16,
1189-1191.
|
 |
|
|
|
|
 |
B.A.Rabinovich,
R.R.Ketchem,
M.Wolfson,
L.Goldstein,
M.Skelly,
and
D.Cosman
(2008).
A role for the MHC class I-like Mill molecules in nutrient metabolism and wound healing.
|
| |
Immunol Cell Biol, 86,
489-496.
|
 |
|
|
|
|
 |
C.H.Chen,
K.R.Dellamaggiore,
C.P.Ouellette,
C.D.Sedano,
M.Lizadjohry,
G.A.Chernis,
M.Gonzales,
F.E.Baltasar,
A.L.Fan,
R.Myerowitz,
and
E.F.Neufeld
(2008).
Aptamer-based endocytosis of a lysosomal enzyme.
|
| |
Proc Natl Acad Sci U S A, 105,
15908-15913.
|
 |
|
|
|
|
 |
D.M.Hudson,
M.J.Krisinger,
T.A.Griffiths,
and
R.T.Macgillivray
(2008).
Neither human hephaestin nor ceruloplasmin forms a stable complex with transferrin.
|
| |
J Cell Biochem, 103,
1849-1855.
|
 |
|
|
|
|
 |
J.Gao,
N.Zhao,
M.D.Knutson,
and
C.A.Enns
(2008).
The hereditary hemochromatosis protein, HFE, inhibits iron uptake via down-regulation of Zip14 in HepG2 cells.
|
| |
J Biol Chem, 283,
21462-21468.
|
 |
|
|
|
|
 |
J.P.Pinto,
P.Ramos,
S.F.de Almeida,
S.Oliveira,
L.Breda,
M.Michalak,
G.Porto,
S.Rivella,
and
M.de Sousa
(2008).
Protective role of calreticulin in HFE hemochromatosis.
|
| |
Free Radic Biol Med, 44,
99.
|
 |
|
|
|
|
 |
K.Pantopoulos
(2008).
Function of the hemochromatosis protein HFE: Lessons from animal models.
|
| |
World J Gastroenterol, 14,
6893-6901.
|
 |
|
|
|
|
 |
M.D.Fleming
(2008).
The regulation of hepcidin and its effects on systemic and cellular iron metabolism.
|
| |
Hematology Am Soc Hematol Educ Program, 2008,
151-158.
|
 |
|
|
|
|
 |
M.I.Hassan,
V.Kumar,
T.P.Singh,
and
S.Yadav
(2008).
Purification and characterization of zinc alpha2-glycoprotein-prolactin inducible protein complex from human seminal plasma.
|
| |
J Sep Sci, 31,
2318-2324.
|
 |
|
|
|
|
 |
N.C.Andrews
(2008).
Forging a field: the golden age of iron biology.
|
| |
Blood, 112,
219-230.
|
 |
|
|
|
|
 |
P.J.Schmidt,
P.T.Toran,
A.M.Giannetti,
P.J.Bjorkman,
and
N.C.Andrews
(2008).
The transferrin receptor modulates Hfe-dependent regulation of hepcidin expression.
|
| |
Cell Metab, 7,
205-214.
|
 |
|
|
|
|
 |
S.F.de Almeida,
and
M.de Sousa
(2008).
The unfolded protein response in hereditary haemochromatosis.
|
| |
J Cell Mol Med, 12,
421-434.
|
 |
|
|
|
|
 |
W.Held,
and
R.A.Mariuzza
(2008).
Cis interactions of immunoreceptors with MHC and non-MHC ligands.
|
| |
Nat Rev Immunol, 8,
269-278.
|
 |
|
|
|
|
 |
A.E.Kogan,
V.L.Filatov,
A.N.Kara,
A.A.Levina,
and
A.G.Katrukha
(2007).
Comparison of soluble and placental transferrin receptors as standards for the determination of soluble transferrin receptor in humans.
|
| |
Int J Lab Hematol, 29,
335-340.
|
 |
|
|
|
|
 |
B.J.Lao,
W.L.Tsai,
F.Mashayekhi,
E.A.Pham,
A.B.Mason,
and
D.T.Kamei
(2007).
Inhibition of transferrin iron release increases in vitro drug carrier efficacy.
|
| |
J Control Release, 117,
403-412.
|
 |
|
|
|
|
 |
E.J.Adams,
Z.S.Juo,
R.T.Venook,
M.J.Boulanger,
H.Arase,
L.L.Lanier,
and
K.C.Garcia
(2007).
Structural elucidation of the m157 mouse cytomegalovirus ligand for Ly49 natural killer cell receptors.
|
| |
Proc Natl Acad Sci U S A, 104,
10128-10133.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
J.Chen,
M.Chloupková,
J.Gao,
T.L.Chapman-Arvedson,
and
C.A.Enns
(2007).
HFE Modulates Transferrin Receptor 2 Levels in Hepatoma Cells via Interactions That Differ from Transferrin Receptor 1-HFE Interactions.
|
| |
J Biol Chem, 282,
36862-36870.
|
 |
|
|
|
|
 |
J.Petrak,
D.Myslivcova,
P.Halada,
R.Cmejla,
J.Cmejlova,
D.Vyoral,
and
C.D.Vulpe
(2007).
Iron-independent specific protein expression pattern in the liver of HFE-deficient mice.
|
| |
Int J Biochem Cell Biol, 39,
1006-1015.
|
 |
|
|
|
|
 |
N.C.Andrews,
and
P.J.Schmidt
(2007).
Iron homeostasis.
|
| |
Annu Rev Physiol, 69,
69-85.
|
 |
|
|
|
|
 |
N.Sheikh,
J.Dudas,
and
G.Ramadori
(2007).
Changes of gene expression of iron regulatory proteins during turpentine oil-induced acute-phase response in the rat.
|
| |
Lab Invest, 87,
713-725.
|
 |
|
|
|
|
 |
P.S.Oates,
and
U.Ahmed
(2007).
Molecular regulation of hepatic expression of iron regulatory hormone hepcidin.
|
| |
J Gastroenterol Hepatol, 22,
1378-1387.
|
 |
|
|
|
|
 |
R.W.Wong,
D.C.Richa,
P.Hahn,
W.R.Green,
and
J.L.Dunaief
(2007).
Iron toxicity as a potential factor in AMD.
|
| |
Retina, 27,
997.
|
 |
|
|
|
|
 |
A.Pietrangelo
(2006).
Hereditary hemochromatosis.
|
| |
Annu Rev Nutr, 26,
251-270.
|
 |
|
|
|
|
 |
A.Pietrangelo
(2006).
Molecular insights into the pathogenesis of hereditary haemochromatosis.
|
| |
Gut, 55,
564-568.
|
 |
|
|
|
|
 |
D.Wernicke,
E.Seipelt,
W.A.Schmidt,
and
E.Gromnica-Ihle
(2006).
Manifestation of rheumatoid arthritis in a patient with hereditary haemochromatosis.
|
| |
Rheumatol Int, 26,
939-941.
|
 |
|
|
|
|
 |
E.Beutler
(2006).
Hemochromatosis: genetics and pathophysiology.
|
| |
Annu Rev Med, 57,
331-347.
|
 |
|
|
|
|
 |
J.Alexander,
and
K.V.Kowdley
(2006).
Effects of iron and HFE mutations on response to therapy in chronic hepatitis C: an ironic interaction?
|
| |
Gastroenterology, 131,
1635-1638.
|
 |
|
|
|
|
 |
K.Natarajan,
A.Hicks,
J.Mans,
H.Robinson,
R.Guan,
R.A.Mariuzza,
and
D.H.Margulies
(2006).
Crystal structure of the murine cytomegalovirus MHC-I homolog m144.
|
| |
J Mol Biol, 358,
157-171.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
L.C.Sullivan,
H.L.Hoare,
J.McCluskey,
J.Rossjohn,
and
A.G.Brooks
(2006).
A structural perspective on MHC class Ib molecules in adaptive immunity.
|
| |
Trends Immunol, 27,
413-420.
|
 |
|
|
|
|
 |
L.M.Palermo,
S.L.Hafenstein,
and
C.R.Parrish
(2006).
Purified feline and canine transferrin receptors reveal complex interactions with the capsids of canine and feline parvoviruses that correspond to their host ranges.
|
| |
J Virol, 80,
8482-8492.
|
 |
|
|
|
|
 |
R.Olson,
C.Dulac,
and
P.J.Bjorkman
(2006).
MHC homologs in the nervous system--they haven't lost their groove.
|
| |
Curr Opin Neurobiol, 16,
351-357.
|
 |
|
|
|
|
 |
S.M.Rizvi,
and
M.Raghavan
(2006).
Direct peptide-regulatable interactions between MHC class I molecules and tapasin.
|
| |
Proc Natl Acad Sci U S A, 103,
18220-18225.
|
 |
|
|
|
|
 |
A.Kogan,
V.Filatov,
N.Gusev,
A.Bereznikova,
O.Kolosova,
and
A.Katrukha
(2005).
Immunological study of complex formation between soluble transferrin receptor and transferrin.
|
| |
Am J Hematol, 79,
281-287.
|
 |
|
|
|
|
 |
A.S.Zhang,
A.P.West,
A.E.Wyman,
P.J.Bjorkman,
and
C.A.Enns
(2005).
Interaction of hemojuvelin with neogenin results in iron accumulation in human embryonic kidney 293 cells.
|
| |
J Biol Chem, 280,
33885-33894.
|
 |
|
|
|
|
 |
C.Ka,
G.Le Gac,
F.Y.Dupradeau,
J.Rochette,
and
C.Férec
(2005).
The Q283P amino-acid change in HFE leads to structural and functional consequences similar to those described for the mutated 282Y HFE protein.
|
| |
Hum Genet, 117,
467-475.
|
 |
|
|
|
|
 |
C.Mura,
O.Raguénes,
V.Scotet,
S.Jacolot,
A.Y.Mercier,
and
C.Férec
(2005).
A 6-year survey of HFE gene test for hemochromatosis diagnosis.
|
| |
Genet Med, 7,
68-73.
|
 |
|
|
|
|
 |
E.M.Teh,
J.Hewitt,
K.C.Ung,
T.A.Griffiths,
V.Nguyen,
S.K.Briggs,
A.B.Mason,
and
R.T.MacGillivray
(2005).
Identification of the epitope of a monoclonal antibody that disrupts binding of human transferrin to the human transferrin receptor.
|
| |
FEBS J, 272,
6344-6353.
|
 |
|
|
|
|
 |
H.Drakesmith,
N.Chen,
H.Ledermann,
G.Screaton,
A.Townsend,
and
X.N.Xu
(2005).
HIV-1 Nef down-regulates the hemochromatosis protein HFE, manipulating cellular iron homeostasis.
|
| |
Proc Natl Acad Sci U S A, 102,
11017-11022.
|
 |
|
|
|
|
 |
I.Theurl,
G.Fritsche,
S.Ludwiczek,
K.Garimorth,
R.Bellmann-Weiler,
and
G.Weiss
(2005).
The macrophage: a cellular factory at the interphase between iron and immunity for the control of infections.
|
| |
Biometals, 18,
359-367.
|
 |
|
|
|
|
 |
J.V.Lunn,
P.M.Gallagher,
S.Hegarty,
M.Kaliszer,
J.Crowe,
P.Murray,
and
D.Bouchier-Hayes
(2005).
The role of hereditary hemochromatosis in aseptic loosening following primary total hip arthroplasty.
|
| |
J Orthop Res, 23,
542-548.
|
 |
|
|
|
|
 |
N.Sharma,
J.Butterworth,
B.T.Cooper,
C.Tselepis,
and
T.H.Iqbal
(2005).
The emerging role of the liver in iron metabolism.
|
| |
Am J Gastroenterol, 100,
201-206.
|
 |
|
|
|
|
 |
P.Aguilar-Martinez,
J.F.Schved,
and
P.Brissot
(2005).
The evaluation of hyperferritinemia: an updated strategy based on advances in detecting genetic abnormalities.
|
| |
Am J Gastroenterol, 100,
1185-1194.
|
 |
|
|
|
|
 |
P.S.Rohrlich,
N.Fazilleau,
F.Ginhoux,
H.Firat,
F.Michel,
M.Cochet,
N.Laham,
M.P.Roth,
S.Pascolo,
F.Nato,
H.Coppin,
P.Charneau,
O.Danos,
O.Acuto,
R.Ehrlich,
J.Kanellopoulos,
and
F.A.Lemonnier
(2005).
Direct recognition by alphabeta cytolytic T cells of Hfe, a MHC class Ib molecule without antigen-presenting function.
|
| |
Proc Natl Acad Sci U S A, 102,
12855-12860.
|
 |
|
|
|
|
 |
R.Olson,
K.E.Huey-Tubman,
C.Dulac,
and
P.J.Bjorkman
(2005).
Structure of a pheromone receptor-associated MHC molecule with an open and empty groove.
|
| |
PLoS Biol, 3,
e257.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
S.Ludwiczek,
I.Theurl,
S.Bahram,
K.Schümann,
and
G.Weiss
(2005).
Regulatory networks for the control of body iron homeostasis and their dysregulation in HFE mediated hemochromatosis.
|
| |
J Cell Physiol, 204,
489-499.
|
 |
|
|
|
|
 |
Y.Gruper,
J.Bar,
E.Bacharach,
and
R.Ehrlich
(2005).
Transferrin receptor co-localizes and interacts with the hemochromatosis factor (HFE) and the divalent metal transporter-1 (DMT1) in trophoblast cells.
|
| |
J Cell Physiol, 204,
901-912.
|
 |
|
|
|
|
 |
A.M.Giannetti,
and
P.J.Björkman
(2004).
HFE and transferrin directly compete for transferrin receptor in solution and at the cell surface.
|
| |
J Biol Chem, 279,
25866-25875.
|
 |
|
|
|
|
 |
C.Gómez-Llorente,
A.Antúnez,
S.Blanco,
A.Suarez,
J.A.Gómez-Capilla,
and
M.E.Farez-Vidal
(2004).
Multiplex analysis of the most common mutations related to hereditary haemochromatosis: two methods combining specific amplification with capillary electrophoresis.
|
| |
Eur J Haematol, 72,
121-129.
|
 |
|
|
|
|
 |
F.De Marco,
R.Liguori,
M.G.Giardina,
M.D'Armiento,
E.Angelucci,
A.Lucariello,
R.Morante,
L.Cimino,
A.Galeota-Lanza,
G.Tarantino,
A.Ascione,
G.Budillon,
R.Vecchione,
R.Martinelli,
M.Matarazzo,
and
V.De Simone
(2004).
High prevalence of non-HFE gene-associated haemochromatosis in patients from southern Italy.
|
| |
Clin Chem Lab Med, 42,
17-24.
|
 |
|
|
|
|
 |
K.Hueffer,
L.M.Palermo,
and
C.R.Parrish
(2004).
Parvovirus infection of cells by using variants of the feline transferrin receptor altering clathrin-mediated endocytosis, membrane domain localization, and capsid-binding domains.
|
| |
J Virol, 78,
5601-5611.
|
 |
|
|
|
|
 |
K.J.Robson,
A.T.Merryweather-Clarke,
E.Cadet,
V.Viprakasit,
M.G.Zaahl,
J.J.Pointon,
D.J.Weatherall,
and
J.Rochette
(2004).
Recent advances in understanding haemochromatosis: a transition state.
|
| |
J Med Genet, 41,
721-730.
|
 |
|
|
|
|
 |
M.W.Hentze,
M.U.Muckenthaler,
and
N.C.Andrews
(2004).
Balancing acts: molecular control of mammalian iron metabolism.
|
| |
Cell, 117,
285-297.
|
 |
|
|
|
|
 |
N.Laham,
R.Rotem-Yehudar,
C.Shechter,
J.E.Coligan,
and
R.Ehrlich
(2004).
Transferrin [corrected] receptor association and endosomal localization of soluble HFE are not sufficient for regulation of cellular iron homeostasis.
|
| |
J Cell Biochem, 91,
1130-1145.
|
 |
|
|
|
|
 |
P.Aisen
(2004).
Transferrin receptor 1.
|
| |
Int J Biochem Cell Biol, 36,
2137-2143.
|
 |
|
|
|
|
 |
Y.Cheng,
O.Zak,
P.Aisen,
S.C.Harrison,
and
T.Walz
(2004).
Structure of the human transferrin receptor-transferrin complex.
|
| |
Cell, 116,
565-576.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
A.M.Giannetti,
P.M.Snow,
O.Zak,
and
P.J.Björkman
(2003).
Mechanism for multiple ligand recognition by the human transferrin receptor.
|
| |
PLoS Biol, 1,
E51.
|
 |
|
|
|
|
 |
A.Pietrangelo
(2003).
Haemochromatosis.
|
| |
Gut, 52,
ii23-ii30.
|
 |
|
|
|
|
 |
A.Pietrangelo
(2003).
Hemochromatosis gene modifies course of hepatitis C viral infection.
|
| |
Gastroenterology, 124,
1509-1523.
|
 |
|
|
|
|
 |
A.S.Zhang,
P.S.Davies,
H.L.Carlson,
and
C.A.Enns
(2003).
Mechanisms of HFE-induced regulation of iron homeostasis: Insights from the W81A HFE mutation.
|
| |
Proc Natl Acad Sci U S A, 100,
9500-9505.
|
 |
|
|
|
|
 |
A.Widera,
F.Norouziyan,
and
W.C.Shen
(2003).
Mechanisms of TfR-mediated transcytosis and sorting in epithelial cells and applications toward drug delivery.
|
| |
Adv Drug Deliv Rev, 55,
1439-1466.
|
 |
|
|
|
|
 |
M.J.Chorney,
Y.Yoshida,
P.N.Meyer,
M.Yoshida,
and
G.S.Gerhard
(2003).
The enigmatic role of the hemochromatosis protein (HFE) in iron absorption.
|
| |
Trends Mol Med, 9,
118-125.
|
 |
|
|
|
|
 |
M.R.Jeng,
P.Adams-Graves,
T.A.Howard,
M.R.Whorton,
C.S.Li,
and
R.E.Ware
(2003).
Identification of hemochromatosis gene polymorphisms in chronically transfused patients with sickle cell disease.
|
| |
Am J Hematol, 74,
243-248.
|
 |
|
|
|
|
 |
O.Zak,
and
P.Aisen
(2003).
Iron release from transferrin, its C-lobe, and their complexes with transferrin receptor: presence of N-lobe accelerates release from C-lobe at endosomal pH.
|
| |
Biochemistry, 42,
12330-12334.
|
 |
|
|
|
|
 |
S.Kotamraju,
Y.Tampo,
A.Keszler,
C.R.Chitambar,
J.Joseph,
A.L.Haas,
and
B.Kalyanaraman
(2003).
Nitric oxide inhibits H2O2-induced transferrin receptor-dependent apoptosis in endothelial cells: Role of ubiquitin-proteasome pathway.
|
| |
Proc Natl Acad Sci U S A, 100,
10653-10658.
|
 |
|
|
|
|
 |
S.Miret,
R.J.Simpson,
and
A.T.McKie
(2003).
Physiology and molecular biology of dietary iron absorption.
|
| |
Annu Rev Nutr, 23,
283-301.
|
 |
|
|
|
|
 |
S.Tomatsu,
K.O.Orii,
R.E.Fleming,
C.C.Holden,
A.Waheed,
R.S.Britton,
M.A.Gutierrez,
S.Velez-Castrillon,
B.R.Bacon,
and
W.S.Sly
(2003).
Contribution of the H63D mutation in HFE to murine hereditary hemochromatosis.
|
| |
Proc Natl Acad Sci U S A, 100,
15788-15793.
|
 |
|
|
|
|
 |
T.A.Rouault
(2003).
How mammals acquire and distribute iron needed for oxygen-based metabolism.
|
| |
PLoS Biol, 1,
E79.
|
 |
|
|
|
|
 |
Y.Liu,
Y.Xiong,
O.V.Naidenko,
J.H.Liu,
R.Zhang,
A.Joachimiak,
M.Kronenberg,
H.Cheroutre,
E.L.Reinherz,
and
J.H.Wang
(2003).
The crystal structure of a TL/CD8alphaalpha complex at 2.1 A resolution: implications for modulation of T cell activation and memory.
|
| |
Immunity, 18,
205-215.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
A.Bomford
(2002).
Genetics of haemochromatosis.
|
| |
Lancet, 360,
1673-1681.
|
 |
|
|
|
|
 |
A.Townsend,
and
H.Drakesmith
(2002).
Role of HFE in iron metabolism, hereditary haemochromatosis, anaemia of chronic disease, and secondary iron overload.
|
| |
Lancet, 359,
786-790.
|
 |
|
|
|
|
 |
A.Waheed,
J.H.Grubb,
X.Y.Zhou,
S.Tomatsu,
R.E.Fleming,
M.E.Costaldi,
R.S.Britton,
B.R.Bacon,
and
W.S.Sly
(2002).
Regulation of transferrin-mediated iron uptake by HFE, the protein defective in hereditary hemochromatosis.
|
| |
Proc Natl Acad Sci U S A, 99,
3117-3122.
|
 |
|
|
|
|
 |
C.N.Roy,
K.P.Blemings,
K.M.Deck,
P.S.Davies,
E.L.Anderson,
R.S.Eisenstein,
and
C.A.Enns
(2002).
Increased IRP1 and IRP2 RNA binding activity accompanies a reduction of the labile iron pool in HFE-expressing cells.
|
| |
J Cell Physiol, 190,
218-226.
|
 |
|
|
|
|
 |
C.Niederau,
and
G.Strohmeyer
(2002).
Strategies for early diagnosis of haemochromatosis.
|
| |
Eur J Gastroenterol Hepatol, 14,
217-221.
|
 |
|
|
|
|
 |
G.Menardi,
L.Perotti,
M.Prucca,
S.Martini,
G.Prandi,
and
G.Peano
(2002).
A very rare association of three mutations of the HFE gene for hemochromatosis.
|
| |
Genet Test, 6,
331-334.
|
 |
|
|
|
|
 |
G.Weiss
(2002).
Iron and immunity: a double-edged sword.
|
| |
Eur J Clin Invest, 32,
70-78.
|
 |
|
|
|
|
 |
H.Drakesmith,
E.Sweetland,
L.Schimanski,
J.Edwards,
D.Cowley,
M.Ashraf,
J.Bastin,
and
A.R.Townsend
(2002).
The hemochromatosis protein HFE inhibits iron export from macrophages.
|
| |
Proc Natl Acad Sci U S A, 99,
15602-15607.
|
 |
|
|
|
|
 |
H.Li,
and
Z.M.Qian
(2002).
Transferrin/transferrin receptor-mediated drug delivery.
|
| |
Med Res Rev, 22,
225-250.
|
 |
|
|
|
|
 |
J.C.Kwok,
and
D.R.Richardson
(2002).
The iron metabolism of neoplastic cells: alterations that facilitate proliferation?
|
| |
Crit Rev Oncol Hematol, 42,
65-78.
|
 |
|
|
|
|
 |
M.De Gobbi,
A.Roetto,
A.Piperno,
R.Mariani,
F.Alberti,
G.Papanikolaou,
M.Politou,
G.Lockitch,
D.Girelli,
S.Fargion,
T.M.Cox,
P.Gasparini,
M.Cazzola,
and
C.Camaschella
(2002).
Natural history of juvenile haemochromatosis.
|
| |
Br J Haematol, 117,
973-979.
|
 |
|
|
|
|
 |
M.T.Dorak,
A.K.Burnett,
and
M.Worwood
(2002).
Hemochromatosis gene in leukemia and lymphoma.
|
| |
Leuk Lymphoma, 43,
467-477.
|
 |
|
|
|
|
 |
N.C.Andrews
(2002).
Metal transporters and disease.
|
| |
Curr Opin Chem Biol, 6,
181-186.
|
 |
|
|
|
|
 |
O.Zak,
K.Ikuta,
and
P.Aisen
(2002).
The synergistic anion-binding sites of human transferrin: chemical and physiological effects of site-directed mutagenesis.
|
| |
Biochemistry, 41,
7416-7423.
|
 |
|
|
|
|
 |
R.E.Fleming,
and
W.S.Sly
(2002).
Mechanisms of iron accumulation in hereditary hemochromatosis.
|
| |
Annu Rev Physiol, 64,
663-680.
|
 |
|
|
|
|
 |
Y.Kohgo,
Y.Torimoto,
and
J.Kato
(2002).
Transferrin receptor in tissue and serum: updated clinical significance of soluble receptor.
|
| |
Int J Hematol, 76,
213-218.
|
 |
|
|
|
|
 |
C.A.Enns
(2001).
Pumping iron: the strange partnership of the hemochromatosis protein, a class I MHC homolog, with the transferrin receptor.
|
| |
Traffic, 2,
167-174.
|
 |
|
|
|
|
 |
D.Berg,
M.Gerlach,
M.B.Youdim,
K.L.Double,
L.Zecca,
P.Riederer,
and
G.Becker
(2001).
Brain iron pathways and their relevance to Parkinson's disease.
|
| |
J Neurochem, 79,
225-236.
|
 |
|
|
|
|
 |
G.Montosi,
A.Donovan,
A.Totaro,
C.Garuti,
E.Pignatti,
S.Cassanelli,
C.C.Trenor,
P.Gasparini,
N.C.Andrews,
and
A.Pietrangelo
(2001).
Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene.
|
| |
J Clin Invest, 108,
619-623.
|
 |
|
|
|
|
 |
I.C.Moura,
M.N.Centelles,
M.Arcos-Fajardo,
D.M.Malheiros,
J.F.Collawn,
M.D.Cooper,
and
R.C.Monteiro
(2001).
Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy.
|
| |
J Exp Med, 194,
417-425.
|
 |
|
|
|
|
 |
O.Dereure,
P.Aguilar-Martinez,
D.Bessis,
P.Perney,
C.Vallat,
B.Guillot,
F.Blanc,
and
J.J.Guilhou
(2001).
HFE mutations and transferrin receptor polymorphism analysis in porphyria cutanea tarda: a prospective study of 36 cases from southern France.
|
| |
Br J Dermatol, 144,
533-539.
|
 |
|
|
|
|
 |
P.A.Gochee,
and
L.W.Powell
(2001).
What's new in hemochromatosis.
|
| |
Curr Opin Hematol, 8,
98.
|
 |
|
|
|
|
 |
P.T.Lieu,
M.Heiskala,
P.A.Peterson,
and
Y.Yang
(2001).
The roles of iron in health and disease.
|
| |
Mol Aspects Med, 22,
1.
|
 |
|
|
|
|
 |
S.V.Ben-Arieh,
B.Zimerman,
N.I.Smorodinsky,
M.Yaacubovicz,
C.Schechter,
I.Bacik,
J.Gibbs,
J.R.Bennink,
J.W.Yewdell,
J.E.Coligan,
H.Firat,
F.Lemonnier,
and
R.Ehrlich
(2001).
Human cytomegalovirus protein US2 interferes with the expression of human HFE, a nonclassical class I major histocompatibility complex molecule that regulates iron homeostasis.
|
| |
J Virol, 75,
10557-10562.
|
 |
|
|
|
|
 |
W.L.Martin,
A.P.West,
L.Gan,
and
P.J.Bjorkman
(2001).
Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding.
|
| |
Mol Cell, 7,
867-877.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
W.Zhong,
W.P.Lafuse,
and
B.S.Zwilling
(2001).
Infection with Mycobacterium avium differentially regulates the expression of iron transport protein mRNA in murine peritoneal macrophages.
|
| |
Infect Immun, 69,
6618-6624.
|
 |
|
|
|
|
 |
A.Akesson,
P.Stål,
and
M.Vahter
(2000).
Phlebotomy increases cadmium uptake in hemochromatosis.
|
| |
Environ Health Perspect, 108,
289-291.
|
 |
|
|
|
|
 |
A.Olsowski,
I.Monden,
G.Krause,
and
K.Keller
(2000).
Cysteine scanning mutagenesis of helices 2 and 7 in GLUT1 identifies an exofacial cleft in both transmembrane segments.
|
| |
Biochemistry, 39,
2469-2474.
|
 |
|
|
|
|
 |
A.T.Merryweather-Clarke,
J.J.Pointon,
A.M.Jouanolle,
J.Rochette,
and
K.J.Robson
(2000).
Geography of HFE C282Y and H63D mutations.
|
| |
Genet Test, 4,
183-198.
|
 |
|
|
|
|
 |
B.D.Schneider,
and
E.A.Leibold
(2000).
Regulation of mammalian iron homeostasis.
|
| |
Curr Opin Clin Nutr Metab Care, 3,
267-273.
|
 |
|
|
|
|
 |
C.Wingren,
M.P.Crowley,
M.Degano,
Y.Chien,
and
I.A.Wilson
(2000).
Crystal structure of a gammadelta T cell receptor ligand T22: a truncated MHC-like fold.
|
| |
Science, 287,
310-314.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
F.Dupradeau,
B.Altenberg-Greulich,
R.Warin,
V.Fuentes,
J.Monti,
and
J.Rochette
(2000).
A 3-dimensional model building by homology of the HFE protein: molecular consequences and application to antibody development.
|
| |
Biochim Biophys Acta, 1481,
213-221.
|
 |
|
|
|
|
 |
H.Drakesmith,
and
A.Townsend
(2000).
The structure and function of HFE.
|
| |
Bioessays, 22,
595-598.
|
 |
|
|
|
|
 |
J.E.Levy,
L.K.Montross,
and
N.C.Andrews
(2000).
Genes that modify the hemochromatosis phenotype in mice.
|
| |
J Clin Invest, 105,
1209-1216.
|
 |
|
|
|
|
 |
J.J.Pointon,
D.Wallace,
A.T.Merryweather-Clarke,
and
K.J.Robson
(2000).
Uncommon mutations and polymorphisms in the hemochromatosis gene.
|
| |
Genet Test, 4,
151-161.
|
 |
|
|
|
|
 |
K.Ikuta,
Y.Fujimoto,
Y.Suzuki,
K.Tanaka,
H.Saito,
M.Ohhira,
K.Sasaki,
and
Y.Kohgo
(2000).
Overexpression of hemochromatosis protein, HFE, alters transferrin recycling process in human hepatoma cells.
|
| |
Biochim Biophys Acta, 1496,
221-231.
|
 |
|
|
|
|
 |
K.Shinkai,
and
R.M.Locksley
(2000).
CD1, tuberculosis, and the evolution of major histocompatibility complex molecules.
|
| |
J Exp Med, 191,
907-914.
|
 |
|
|
|
|
 |
M.Wessling-Resnick
(2000).
Iron transport.
|
| |
Annu Rev Nutr, 20,
129-151.
|
 |
|
|
|
|
 |
N.C.Andrews
(2000).
Iron metabolism: iron deficiency and iron overload.
|
| |
Annu Rev Genomics Hum Genet, 1,
75-98.
|
 |
|
|
|
|
 |
O.Rosmorduc,
R.Poupon,
I.Nion,
D.Wendum,
J.Feder,
G.Béréziat,
and
B.Hermelin
(2000).
Differential HFE allele expression in hemochromatosis heterozygotes.
|
| |
Gastroenterology, 119,
1075-1086.
|
 |
|
|
|
|
 |
R.D.Press
(2000).
Iron beware: a common HFE gene polymorphism may prevent the accurate molecular diagnosis of homozygous hemochromatosis in low-risk, but not high-risk groups.
|
| |
Hepatology, 31,
540-542.
|
 |
|
|
|
|
 |
R.Gottschalk,
C.Seidl,
S.Schilling,
A.Braner,
E.Seifried,
D.Hoelzer,
and
J.P.Kaltwasser
(2000).
Iron-overload and genotypic expression of HFE mutations H63D/C282Y and transferrin receptor Hin6I and BanI polymorphism in german patients with hereditary haemochromatosis.
|
| |
Eur J Immunogenet, 27,
129-134.
|
 |
|
|
|
|
 |
R.S.Eisenstein
(2000).
Iron regulatory proteins and the molecular control of mammalian iron metabolism.
|
| |
Annu Rev Nutr, 20,
627-662.
|
 |
|
|
|
|
 |
S.Cunningham-Rundles,
P.J.Giardina,
R.W.Grady,
C.Califano,
P.McKenzie,
and
M.De Sousa
(2000).
Effect of transfusional iron overload on immune response.
|
| |
J Infect Dis, 182,
S115-S121.
|
 |
|
|
|
|
 |
S.Distante,
J.P.Berg,
K.Lande,
E.Haug,
and
H.Bell
(2000).
HFE gene mutation (C282Y) and phenotypic expression among a hospitalised population in a high prevalence area of haemochromatosis.
|
| |
Gut, 47,
575-579.
|
 |
|
|
|
|
 |
S.Moalem,
M.E.Percy,
D.F.Andrews,
T.P.Kruck,
S.Wong,
A.J.Dalton,
P.Mehta,
B.Fedor,
and
A.C.Warren
(2000).
Are hereditary hemochromatosis mutations involved in Alzheimer disease?
|
| |
Am J Med Genet, 93,
58-66.
|
 |
|
|
|
|
 |
S.Sheth,
and
G.M.Brittenham
(2000).
Genetic disorders affecting proteins of iron metabolism: clinical implications.
|
| |
Annu Rev Med, 51,
443-464.
|
 |
|
|
|
|
 |
T.L.Chapman,
A.P.Heikema,
A.P.West,
and
P.J.Bjorkman
(2000).
Crystal structure and ligand binding properties of the D1D2 region of the inhibitory receptor LIR-1 (ILT2).
|
| |
Immunity, 13,
727-736.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
V.Ghetie,
and
E.S.Ward
(2000).
Multiple roles for the major histocompatibility complex class I- related receptor FcRn.
|
| |
Annu Rev Immunol, 18,
739-766.
|
 |
|
|
|
|
 |
A.E.Ten Elshof,
G.M.Brittenham,
K.A.Chorney,
M.J.Page,
G.Gerhard,
E.E.Cable,
and
M.J.Chorney
(1999).
Gamma delta intraepithelial lymphocytes drive tumor necrosis factor-alpha responsiveness to intestinal iron challenge: relevance to hemochromatosis.
|
| |
Immunol Rev, 167,
223-232.
|
 |
|
|
|
|
 |
A.Roetto,
A.Totaro,
M.Cazzola,
M.Cicilano,
S.Bosio,
G.D'Ascola,
M.Carella,
L.Zelante,
A.L.Kelly,
T.M.Cox,
P.Gasparini,
and
C.Camaschella
(1999).
Juvenile hemochromatosis locus maps to chromosome 1q.
|
| |
Am J Hum Genet, 64,
1388-1393.
|
 |
|
|
|
|
 |
A.Waheed,
S.Parkkila,
J.Saarnio,
R.E.Fleming,
X.Y.Zhou,
S.Tomatsu,
R.S.Britton,
B.R.Bacon,
and
W.S.Sly
(1999).
Association of HFE protein with transferrin receptor in crypt enterocytes of human duodenum.
|
| |
Proc Natl Acad Sci U S A, 96,
1579-1584.
|
 |
|
|
|
|
 |
B.R.Bacon,
L.W.Powell,
P.C.Adams,
T.F.Kresina,
and
J.H.Hoofnagle
(1999).
Molecular medicine and hemochromatosis: at the crossroads.
|
| |
Gastroenterology, 116,
193-207.
|
 |
|
|
|
|
 |
C.N.Roy,
D.M.Penny,
J.N.Feder,
and
C.A.Enns
(1999).
The hereditary hemochromatosis protein, HFE, specifically regulates transferrin-mediated iron uptake in HeLa cells.
|
| |
J Biol Chem, 274,
9022-9028.
|
 |
|
|
|
|
 |
D.G.Myszka
(1999).
Survey of the 1998 optical biosensor literature.
|
| |
J Mol Recognit, 12,
390-408.
|
 |
|
|
|
|
 |
D.H.Crawford,
and
G.A.Ramm
(1999).
Haemochromatosis.
|
| |
Trends Endocrinol Metab, 10,
14-17.
|
 |
|
|
|
|
 |
D.H.Crawford,
and
L.M.Fletcher
(1999).
Utility of genotyping in diagnosis of genetic haemochromatosis.
|
| |
J Gastroenterol Hepatol, 14,
401-402.
|
 |
|
|
|
|
 |
D.Mahadevan,
and
J.W.Saldanha
(1999).
The extracellular regions of PSMA and the transferrin receptor contain an aminopeptidase domain: implications for drug design.
|
| |
Protein Sci, 8,
2546-2549.
|
 |
|
|
|
|
 |
F.A.Arosa,
O.de Jesus,
G.Porto,
A.M.Carmo,
and
M.de Sousa
(1999).
Calreticulin is expressed on the cell surface of activated human peripheral blood T lymphocytes in association with major histocompatibility complex class I molecules.
|
| |
J Biol Chem, 274,
16917-16922.
|
 |
|
|
|
|
 |
H.Zoller,
A.Pietrangelo,
W.Vogel,
and
G.Weiss
(1999).
Duodenal metal-transporter (DMT-1, NRAMP-2) expression in patients with hereditary haemochromatosis.
|
| |
Lancet, 353,
2120-2123.
|
 |
|
|
|
|
 |
J.J.Powell,
R.Jugdaohsingh,
and
R.P.Thompson
(1999).
The regulation of mineral absorption in the gastrointestinal tract.
|
| |
Proc Nutr Soc, 58,
147-153.
|
 |
|
|
|
|
 |
J.N.Feder
(1999).
The hereditary hemochromatosis gene (HFE): a MHC class I-like gene that functions in the regulation of iron homeostasis.
|
| |
Immunol Res, 20,
175-185.
|
 |
|
|
|
|
 |
J.Rochette,
J.J.Pointon,
C.A.Fisher,
G.Perera,
M.Arambepola,
D.S.Arichchi,
S.De Silva,
J.L.Vandwalle,
J.P.Monti,
J.M.Old,
A.T.Merryweather-Clarke,
D.J.Weatherall,
and
K.J.Robson
(1999).
Multicentric origin of hemochromatosis gene (HFE) mutations.
|
| |
Am J Hum Genet, 64,
1056-1062.
|
 |
|
|
|
|
 |
K.Hashimoto,
K.Okamura,
H.Yamaguchi,
M.Ototake,
T.Nakanishi,
and
Y.Kurosawa
(1999).
Conservation and diversification of MHC class I and its related molecules in vertebrates.
|
| |
Immunol Rev, 167,
81.
|
 |
|
|
|
|
 |
K.Maenaka,
and
E.Y.Jones
(1999).
MHC superfamily structure and the immune system.
|
| |
Curr Opin Struct Biol, 9,
745-753.
|
 |
|
|
|
|
 |
L.C.Kühn
(1999).
Iron overload: molecular clues to its cause.
|
| |
Trends Biochem Sci, 24,
164-166.
|
 |
|
|
|
|
 |
L.M.Cullen,
G.J.Anderson,
G.A.Ramm,
E.C.Jazwinska,
and
L.W.Powell
(1999).
Genetics of hemochromatosis.
|
| |
Annu Rev Med, 50,
87-98.
|
 |
|
|
|
|
 |
L.M.Sánchez,
A.J.Chirino,
and
P.Bjorkman
(1999).
Crystal structure of human ZAG, a fat-depleting factor related to MHC molecules.
|
| |
Science, 283,
1914-1919.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
L.Salter-Cid,
A.Brunmark,
Y.Li,
D.Leturcq,
P.A.Peterson,
M.R.Jackson,
and
Y.Yang
(1999).
Transferrin receptor is negatively modulated by the hemochromatosis protein HFE: implications for cellular iron homeostasis.
|
| |
Proc Natl Acad Sci U S A, 96,
5434-5439.
|
 |
|
|
|
|
 |
N.C.Andrews,
M.D.Fleming,
and
J.E.Levy
(1999).
Molecular insights into mechanisms of iron transport.
|
| |
Curr Opin Hematol, 6,
61-64.
|
 |
|
|
|
|
 |
P.Aisen,
M.Wessling-Resnick,
and
E.A.Leibold
(1999).
Iron metabolism.
|
| |
Curr Opin Chem Biol, 3,
200-206.
|
 |
|
|
|
|
 |
P.Ponka,
and
C.N.Lok
(1999).
The transferrin receptor: role in health and disease.
|
| |
Int J Biochem Cell Biol, 31,
1111-1137.
|
 |
|
|
|
|
 |
R.E.Fleming,
M.C.Migas,
X.Zhou,
J.Jiang,
R.S.Britton,
E.M.Brunt,
S.Tomatsu,
A.Waheed,
B.R.Bacon,
and
W.S.Sly
(1999).
Mechanism of increased iron absorption in murine model of hereditary hemochromatosis: increased duodenal expression of the iron transporter DMT1.
|
| |
Proc Natl Acad Sci U S A, 96,
3143-3148.
|
 |
|
|
|
|
 |
S.Bahram,
S.Gilfillan,
L.C.Kühn,
R.Moret,
J.B.Schulze,
A.Lebeau,
and
K.Schümann
(1999).
Experimental hemochromatosis due to MHC class I HFE deficiency: immune status and iron metabolism.
|
| |
Proc Natl Acad Sci U S A, 96,
13312-13317.
|
 |
|
|
|
|
 |
T.L.Chapman,
A.P.Heikeman,
and
P.J.Bjorkman
(1999).
The inhibitory receptor LIR-1 uses a common binding interaction to recognize class I MHC molecules and the viral homolog UL18.
|
| |
Immunity, 11,
603-613.
|
 |
|
|
|
|
 |
V.M.Braud,
D.S.Allan,
and
A.J.McMichael
(1999).
Functions of nonclassical MHC and non-MHC-encoded class I molecules.
|
| |
Curr Opin Immunol, 11,
100-108.
|
 |
|
|
|
|
 |
W.J.Griffiths,
A.L.Kelly,
and
T.M.Cox
(1999).
Inherited disorders of iron storage and transport.
|
| |
Mol Med Today, 5,
431-438.
|
 |
|
|
|
|
 |
A.W.Wolkoff,
F.J.Suchy,
R.H.Moseley,
P.J.Meier,
J.L.Gollan,
N.Freimer,
J.G.Fitz,
J.L.Boyer,
P.D.Berk,
and
B.F.Scharschmidt
(1998).
Advances in hepatic transport: molecular mechanisms, genetic disorders, and treatment. A summary of the 1998 AASLD single topic conference.
|
| |
Hepatology, 28,
1713-1719.
|
 |
|
|
|
|
 |
C.N.Gross,
A.Irrinki,
J.N.Feder,
and
C.A.Enns
(1998).
Co-trafficking of HFE, a nonclassical major histocompatibility complex class I protein, with the transferrin receptor implies a role in intracellular iron regulation.
|
| |
J Biol Chem, 273,
22068-22074.
|
 |
|
|
|
|
 |
D.H.Fremont,
F.Crawford,
P.Marrack,
W.A.Hendrickson,
and
J.Kappler
(1998).
Crystal structure of mouse H2-M.
|
| |
Immunity, 9,
385-393.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
M.D'Amato,
A.Macrí,
D.Griso,
G.Biolcati,
and
F.Ameglio
(1998).
Are His63Asp or Cys282Tyr HFE mutations associated with porphyria cutanea tarda? Data of patients from central and southern Italy.
|
| |
J Invest Dermatol, 111,
1241-1242.
|
 |
|
|
|
|
 |
T.A.Rouault
(1998).
Hereditary hemochromatosis--sometimes having a real complex can be a good thing.
|
| |
Hepatology, 28,
890-891.
|
 |
|
|
|
|
 |
T.M.Cox,
and
A.L.Kelly
(1998).
Haemochromatosis: an inherited metal and toxicity syndrome.
|
| |
Curr Opin Genet Dev, 8,
274-281.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
|